Companies / Cereno Scientific AB
CRNO-B.STCereno Scientific AB
1 active clinical study registered on ClinicalTrials.gov, the most advanced in Phase 2. Next estimated primary completion: 2 Feb 2029.
Clinical pipeline
| Primary completion | Phase | Status | Condition and study |
|---|---|---|---|
| 2 Feb 2029 | Phase 2? | Not yet recruiting | Pulmonary Arterial Hypertension CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension · NCT07761572 |
Source: ClinicalTrials.gov, studies with the company as sponsor and an active status. Data fetched 7 October 2026.
Recent news
Headlines from other publications, linked to the original. We do not rewrite or summarise them. Analyst ratings and price targets are the opinion of the cited source, not ours.
- Cereno Scientific reports positive Phase 1 bridging data for CS014 in pulmonary hypertension
- Cereno Scientific Reports Positive Results From Study
- RX Securities reiterates buy on Cereno Scientific following positive Phase 1 data for CS014
- Cereno's bridge study strengthens plan to skip phase IIa
- Cereno Scientific Reports Positive Topline Results from CS014 Phase I PK-bridging Study, Strengthening Intended Direct Path toward Phase IIb in PH-ILD
- Cereno sees support for direct path to Phase IIb with CS014
- Cereno Scientific AB (CRNO_B) Posts Positive CS014 PK-Bridging, Plans Direct Path to Phase IIb
- Cereno's bridge study strengthens plan to skip phase IIa
- Cereno Scientific meets investors at conference in New York, CEO: important to broaden our dialogue ahead of the next phase
- Cereno Scientific to engage US and international investors at H.C. Wainwright 28th Annual Global Investment Conference in New York
- Cereno Scientific (OM:CRNO B) Stock Trails Revenue Spike As Cash Runway Shrinks
- Cereno Scientific (OM:CRNO B) Stock Trails Revenue Spike As Cash Runway Shrinks